ROSEN, HIGHLY RANKED INVESTOR COUNSEL, Encourages MoonLake Immunotherapeutics Investors to Secure Counsel Before Important Deadline in Securities Class Action - MLTXNovember 18, 2025 4:32 PM EST | Source: The Rosen Law Firm PANew York, New York--(Newsfile Corp. - November 18, 2025) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of MoonLake Immunotherapeutics (NASDAQ: MLTX) between March 10, 2024 and September 29, 2025, both dates inclusive (the "Cl ...

Accessibility StatementSkip Navigation DUBLIN, Nov. 18, 2025 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the Company will participate in Citi's 2025 Global Healthcare Conference. Company management will participate in a fireside chat on Tuesday, December 2, 2025, at 6:45 a.m. PST / 9:45 a.m. EST / 2:45 p.m. GMT. SOURCE Jazz Pharmaceuticals plc 21% more press release views with Request a Demo Also from this source Positive HERIZON-GEA-01 Phase 3 Results Support Ziihera® (zan ...

Accessibility StatementSkip Navigation SYDNEY, Nov. 18, 2025 /PRNewswire/ -- Kazia Therapeutics Limited (Nasdaq: KZIA), an oncology-focused drug development company, today announced that a patient with stage IV triple-negative breast cancer (TNBC) treated under an FDA-authorized single-patient expanded access protocol combining paxalisib with pembrolizumab (Keytruda®) and standard chemotherapy has achieved an initial immune-complete response (iCR) per iRECIST criteria. This outcome suggests a profound radio ...

November 18, 2025 – 10:01 PM CET Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, announced the results of its Extraordinary General Meeting of shareholders held on November 18, 2025. The remuneration policy, which was the sole voting item on the agenda, was approved by the required majority of votes. The Company’s remuneration policy was approved by a 95.67% majority, with 91.1 ...

ASX today – Hump day may see little action for Australian shares, with some traders shellshocked by yesterday's $60 billion selloff (the largest since Trump's Liberation Day dives) and others battening down the hatches before the long-awaited Nvidia results coming on Thursday morning (Aus). Listen to the HotCopper podcast for in-depth discussions and insights on all the biggest headlines from throughout the week. On Spotify, Apple, and more. ASX futures are now pointing to the barest of gains, up just under ...

Core Insights - Bicycle Therapeutics plc is under investigation for possible violations of federal securities laws, as announced by Levi & Korsinsky [1] - RBC Capital Markets downgraded Bicycle Therapeutics from Outperform to Sector Perform due to delays in the development of its drug, zelenectide pevedotin, which is intended for metastatic urothelial cancer [2] - Following the downgrade, Bicycle's American Depositary Receipt (ADR) price dropped over 7% on the same day [3] Company Developments - The delay in the drug's development is attributed to the decision to push dose selection to the first quarter of 2026, which raises concerns about increased competition in the urothelial cancer treatment market [2] - The competitive landscape is highlighted by the potential impact of a competing product from Pfizer, which may benefit from any further delays in Bicycle's drug development [2] Legal Context - Levi & Korsinsky LLP has a strong reputation in securities litigation, having secured significant settlements for shareholders and being recognized as one of the top firms in the United States for securities class actions [4]

Accessibility StatementSkip Navigation WHY DJS LAW GROUP? DJS Law Group's primary focus is to enhance investor return through balanced counseling and aggressive advocacy. We specialize in securities class actions, corporate governance litigation, and domestic/international M&A appraisals. Our clients are some of the largest and most sophisticated hedge funds and alternative asset managers in the world. The litigation claims of our clients are extraordinarily valuable assets that demand respect, focus, and ...

Nov 18, 2025 2:54 PM Eastern Standard Time The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation. This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics. SKYE Investors Have Opportunity to Lead Skye Bioscience, Inc. Securities Fraud Lawsuit With the Schall Law Firm Share LOS ANGELES--(BUSINESS WIRE)--The Schall Law Firm, a national shareholder rights ...

Arrowhead Pharmaceuticals (NasdaqGS:ARWR) Update / Briefing November 18, 2025 01:30 PM ET Speaker2Good afternoon and welcome to the Arrowhead Pharmaceuticals Redemplo FDA Approval Conference Call. At this time, all attendees are in listen-only mode. A question-and-answer session will follow the presentation. As a reminder, this call is being recorded and a replay will be made available on the Arrowhead website following the conclusion of the event. I'd now like to turn the call over to Vince Anzalone, Vice ...

Olema Pharmaceuticals, Inc. (OLMA) shares surged 142.25 percent to $20.64 in Tuesday trading, gaining $12.12 despite no new company-specific news driving the move.The stock opened sharply higher at $26.45 compared with a previous close of $8.52 on the Nasdaq. Shares have traded between $18.11 and $27.17 so far today, with heavy volume of 67,871,753 far above the average of 1,194,014.Over the past 52 weeks, Olema shares have traded between $2.86 and $27.17. For comments and feedback contact: editorial@rttne ...